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Sulfation of carbohydrate residues occurs on a variety of glycans destined for secretion,
and this modiﬁcation is essential for efﬁcient matrix-based signal transduction. Heparan
sulfate (HS) glycosaminoglycans control physiological functions ranging from blood
coagulation to cell proliferation. HS biosynthesis involves membrane-bound Golgi sulfo-
transferases, including HS 2-O-sulfotransferase (HS2ST), which transfers sulfate from the
cofactor PAPS (30-phosphoadenosine 50-phosphosulfate) to the 2-O position of α-L-iduro-
nate in the maturing polysaccharide chain. The current lack of simple non-radioactive
enzyme assays that can be used to quantify the levels of carbohydrate sulfation hampers
kinetic analysis of this process and the discovery of HS2ST inhibitors. In the present
paper, we describe a new procedure for thermal shift analysis of puriﬁed HS2ST. Using
this approach, we quantify HS2ST-catalysed oligosaccharide sulfation using a novel syn-
thetic ﬂuorescent substrate and screen the Published Kinase Inhibitor Set, to evaluate
compounds that inhibit catalysis. We report the susceptibility of HS2ST to a variety of
cell-permeable compounds in vitro, including polyanionic polar molecules, the protein
kinase inhibitor rottlerin and oxindole-based RAF kinase inhibitors. In a related study,
published back-to-back with the present study, we demonstrated that tyrosyl protein sul-
fotranferases are also inhibited by a variety of protein kinase inhibitors. We propose that
appropriately validated small-molecule compounds could become new tools for rapid
inhibition of glycan (and protein) sulfation in cells, and that protein kinase inhibitors might
be repurposed or redesigned for the speciﬁc inhibition of HS2ST.
Introduction
Biological sulfation is a widespread reversible covalent modiﬁcation found throughout nature [1]. The
regulated sulfation of saccharides is critical for cellular signalling, including regulatory interactions
between extracellular glycoproteins that control signal transduction and high-afﬁnity interactions
between different cellular surfaces [2]. In addition to providing mechanical strength, the sulfate-rich
extracellular matrix also represents a hub for sulfation-based communication through growth factor
signalling [3]. For example, FGF–receptor interactions and intracellular signalling to the ERK pathway
are blunted in the absence of appropriate 2-O sulfation driven by heparan sulfate (HS)-modifying
enzymes [4–9], while sulfation of the tetrasaccharide Sialyl LewisX antigen on glycolipids controls
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leukocyte adhesion to the endothelium during inﬂammation [10,11]. Inappropriate glycan sulfation can there-
fore underlie aspects of abnormal signalling, infection, inﬂammation and, increasingly, human neuropathies
[12], suggesting that targeting of carbohydrate sulfation dynamics using small-molecule enzyme inhibitors may
be of value in both basic and translational research [13]. Indeed, the current limited chemical toolbox to
rapidly modify and study glycan sulfation is based around small-molecule inhibitors of sulfatase-2 (Sulf-2),
such as OKN-007 [14] or heparanase inhibitors and HS mimics, including roneparstat and PG545, which have
been employed for basic and clinical investigation [15].
Glycan sulfotransferases (STs) can be classiﬁed into several families depending on the positional substrate
speciﬁcity of enzymes for their respective sugar substrates [16,17]. HS 2-O-sulfotransferase (HS2ST) is required
for the generation of HS, which is an abundant unbranched extracellular glycosaminoglycan with key roles in a
range of physiological functions, most notably growth factor-dependent signalling related to development, cell
migration and inﬂammation [18]. HS2ST is a transmembrane protein whose catalytic domain faces into the
lumen of the Golgi compartment, and catalyses the sulfation of iduronic acid and, to a lesser extent
β-D-glucouronate (GlcA), during the enzymatic assembly of secretory HS proteoglycans [18,19]. HS2ST trans-
fers the sulfo moiety from PAPS (30-phosphoadenosine 50-phosphosulfate) sulfate donor to the C2 hydroxyl of
IdoA that lies adjacent to an N-sulfated glucosamine residue, generating a 2-O-sulfated saccharide unit
[20–22]. Removal of the sulfate by endosulfatases such as Sulf-2, or more general HS processing by heparanase,
also contributes to the complex physiological patterns of carbohydrate editing found in vivo [23].
The analysis of murine models lacking HS2ST reveals central roles for 2-O-sulfated HS in kidney develop-
ment and neuronal function, and for signalling through WNT- and FGF-dependent pathways [8,18,24–26].
However, in order to carefully control and examine the dynamics and structural heterogeneity of 2-O sulfation
patterns in HS, which are the consequences of nontemplate-based synthesis of HS and complex dynamic sulfa-
tion patterns, new small-molecule approaches for the direct, reversible inhibition of sulfotransferase enzymes
are urgently required. In particular, these need to be deployed using chemical biology strategies to overcome
deﬁciencies associated with genetic disruption approaches relevant to development and/or compensatory glyco-
sylation or signalling mechanisms [27].
Mechanistic parallels between the enzymatic pathway of biological sulfation by sulfotransferases [28]
and phosphorylation by protein kinases [29] are apparent since both enzyme classes transfer charged
chemical units from an adenine-based nucleotide cofactor to a (usually) polymeric acceptor structure. The
biological analysis of protein kinases, which are thought to employ a similar ‘in-line’ enzyme reaction as
the 2-O-sulfotransferases [28] when transferring phosphate to peptide targets [30], has been revolutionised
by the synthesis and wide availability of small-molecule inhibitors [31]. Many of these compounds were origin-
ally discovered in screens with ATP-competitive inhibitor libraries using oncology-associated target enzymes
[32]. Protein kinases have proved to be exceptional targets for the development of therapeutic agents in
humans, and ∼50 kinase inhibitors have been approved, or will soon be approved, for cancer and anti-
inﬂammatory indications [33]. To help diversify and accelerate this process, validated open-source panels of
such inhibitors, such as the Public Kinase Inhibitor Set (PKIS), have been assembled for screening purposes,
constituting a variety of chemotypes for unbiased small-molecule inhibitor discovery, which can be applied to a
diverse range of protein targets [34].
The analysis of carbohydrate sulfation currently relies heavily on genetic, biophysical (NMR) and combina-
torial organic chemistry and enzymatic analysis, with only a handful of low-afﬁnity inhibitors of carbohydrate
sulfotransferases ever having been disclosed [13,35]. More recently, a relatively potent inhibitor of the related
type IV aryl sulfotransferase [36] and much lower afﬁnity oestrogen sulfotransferase inhibitors [37–39] were
reported. Owing to a lack of any selective chemical tool compounds, cellular glycan sulfation remains under-
studied, relying on non-speciﬁc cellular methods such as chlorate exposure [40], and the ﬁeld remains ripe for
technological innovation and new chemical biology approaches. Early attempts to discover such molecules
among small, relatively unfocussed, kinase-based libraries led to the discovery of low-afﬁnity purine and
tyrphostin-based inhibitory compounds, which are well-established chemical classes of protein kinase inhibitor
[35]. This raises the question as to whether PAPS-dependent sulfotransferases are general inhibitory targets for
new or repurposed small molecules that target nucleotide-binding sites, especially broader families of com-
pounds originally developed as protein kinase inhibitors. However, the low throughput nature of radioactive
(35S-PAPS) TLC or HPLC-based assays typically used for sulfotransferase analysis [35,41,42], and the relatively
low potency of current hits, argues for new approaches to assay and screen more diverse selections of focused
or larger chemical libraries.
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In the present paper, and in a related study employing tyrosyl protein sulfotranserases [43], we describe
novel in vitro methods for assaying recombinant HS2ST, one of which employs a ﬂuorescent-based detection
system with a hexasaccharide substrate. PAPS-dependent sulfation of the substrate at the 2-O position of the
IdoA residue leads to a change in substrate chemical properties, which can be detected as a real-time mobility
shift in a high-throughput microﬂuidic assay format originally developed for the analysis of peptide phosphor-
ylation [44,45]. We exploit this assay alongside differential scanning ﬂuorimetry (DSF) to screen a small-
molecule PKIS library, characterising HS2ST susceptibility towards a variety of cell-permeable compounds. We
propose that appropriately validated small-molecule ligands might become invaluable probes for rapid cellular
inhibition of HS2STs, and that further iteration could lead to the discovery and synthesis (or repurposing) of
small molecules, including compound classes currently employed as kinase inhibitors, to probe cellular HS2ST
function.
Experimental
Materials and methods
Chemicals and compounds
Porcine intestinal heparin was from Sigma, oligomeric saccharide standards, termed dp2-dp12, where
dp = degree of polymerisation [46], were from Iduron (Manchester, U.K.). Polymeric sulfated heparin derivatives
(Table 1) were synthesised in-house as previously described [47]. N-sulfated, ﬂuorescein-tagged hexasaccharide
glycan substrates (GlcNS–GlcA–GlcNS–IdoA–GlcNS–GlcA-ﬂuorescein, where S = sulfation) containing either
L-IdoA or GlcA residues at the third residue from the reducing end (to which a linker and the ﬂuorophore were
conjugated) were both purchased from GLYCAN therapeutics (Chapel Hill, NC). All standard laboratory bio-
chemicals were purchased from either Melford or Sigma and were of the highest analytical quality. PAPS (adeno-
sine 30-phosphate 50-phosphosulfate, lithium salt hydrate), APS (adenosine 50-phosphosulfate, sodium salt), PAP
(adenosine 30–50-diphosphate, disodium salt), CoA (coenzyme A, sodium salt) dephosphoCoA (30-dephosphoCoA,
sodium salt hydrate), ATP (adenosine 50-triphosphate, disodium salt hydrate), ADP (adenosine 50-diphosphate, dis-
odium salt), AMP (adenosine 50-monophosphate, sodium salt), GTP (guanosine 50-triphosphate, sodium salt
hydrate) or cAMP (adenosine 30,50-cyclic monophosphate, sodium salt) were all purchased from Sigma and stored
at −80°C to minimise degradation. Rottlerin, suramin, aurintricarboxylic acid and all named kinase inhibitors
were purchased from Sigma, BD Laboratories, Selleck or Tocris.
Cloning, recombinant protein production and SDS–PAGE
Chicken HS2ST (isoform 1), which exhibits ∼92% identity with human HS2ST, was a kind gift from Dr Lars
Pedersen (NIH, U.S.A.) and was expressed in the Rosetta-gami (DE3) strain of Escherichia coli from a modiﬁed
pMAL-c2x plasmid encoding an N-terminal maltose-binding protein (MBP) afﬁnity tag. Trimeric recombinant
HS2ST1 enzyme was partially puriﬁed using immobilised amylose afﬁnity chromatography directly from the
cleared bacterial extract, essentially as described previously [28]. MBP-HS2ST was eluted with maltose and
further puriﬁed by SEC using a HiLoad 16/600 Superdex 200 column (GE Healthcare), which was equilibrated
Table 1 Predominant substitution patterns of differentially sulfated heparin derivatives described in the
present study
Analogue Predominant repeat IdoUA-2 GlcN-6 GlcN-2 IdoUA-3 GlcN-3a
1 (Heparin) I2SA
6SNs SO3 SO

3 SO

3 OH OH
2 I2SA
6SNAc SO3 SO

3 COCH3 OH OH
3 I2OHA
6SNs OH SO3 SO

3 OH OH
4 I2SA
6OHNs SO3 OH SO

3 OH OH
5 I2OHA
6SNAc OH SO3 COCH3 OH OH
6 I2SA
6OHNAc SO3 OH COCH3 OH OH
7 I2OHA
6OHNs OH OH SO3 OH OH
8 I2OHA
6OHNAc OH OH COCH3 OH OH
9 I2S,3SA
6S
3SNs SO3 SO

3 SO

3 SO

3 SO

3
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in 50 mM Tris–Cl, pH 7.4, 100 mM NaCl, 10% (v/v) glycerol and 1 mM DTT. Prior to analysis, puriﬁed pro-
teins were snap frozen in liquid nitrogen and stored at −80°C. This procedure generated HS2ST of >95%
purity. Proteolytic removal of the MBP afﬁnity tag from HS2ST (after re-cloning with MBP and 3C protease
sites into the plasmid pOPINM) led to rapid HS2ST denaturation, based on rapid precipitation, so for the pro-
cedures described in the present paper the MBP afﬁnity tag was left intact. For SDS–PAGE, proteins were dena-
tured in Laemmli sample buffer, heated at 95°C for 5 min and then analysed by SDS–PAGE with 10% (v/v)
polyacrylamide gels. Gels were stained and destained using a standard Coomassie Brilliant Blue protocol. To
generate catalytically inactive MBP-HS2ST, the conserved catalytic His residue (His 142) was mutated to Ala
using standard PCR procedures [48]. The mutant enzyme was puriﬁed as described above.
DSF-based ﬂuorescent assays
Thermal shift/stability assays (TSAs) were performed using a StepOnePlus Real-Time PCR machine (Life
Technologies) using SYPRO-Orange dye (emission maximum 570 nm, Invitrogen), with thermal ramping
between 20 and 95°C in 0.3°C step intervals per data point to induce denaturation in the presence or absence
of test biochemicals or small-molecule inhibitors, as previously described [48]. HS2ST was assayed at a ﬁnal
concentration of 5 μM in 50 mM Tris–Cl (pH 7.4) and 100 mM NaCl. Final DMSO concentration in the pres-
ence or absence of the indicated concentrations of ligand was no higher than 4% (v/v). Normalised data were
processed using the Boltzmann equation to generate sigmoidal denaturation curves, and average Tm/ΔTm values
were calculated as described using the GraphPad Prism software [48].
Microﬂuidics-based sulfation assay
N-sulfated, ﬂuorescein-tagged hexasaccharide glycan substrate (GlcNS–GlcA–GlcNS–IdoA–GlcNS–
GlcA-ﬂuorescein, where S = sulfation) containing either L-IdoA or D-GlcA residues at the third residue from
the reducing end (to which a linker and the ﬂuorophore were conjugated) was both purchased from GLYCAN
therapeutics (www.glycantherapeutics.com). The ﬂuorescein group attached to the reducing end of the glycan
substrate possesses a maximal emission absorbance of ∼525 nm, which can be detected by the EZ Reader via
LED-induced ﬂuorescence. Chemically modiﬁed heparins were generated through a published procedure [47],
whereas oligosaccharides from Iduron were generated enzymatically [4,49]. Non-radioactive microﬂuidic mobil-
ity shift carbohydrate sulfation assays were optimised in solution with a 12-sipper chip coated with CR8
reagent and a PerkinElmer EZ Reader II system [50] using EDTA-based separation buffer and real-time kinetic
evaluation of substrate sulfation. Pressure and voltage settings were adjusted manually to afford optimal separ-
ation of the sulfated product and non-sulfated hexasaccharide substrate, with a sample (sip) volume of 20 nl,
and total assay times appropriate for the experiment. Individual sulfation assays were assembled in a 384-well
plate in a volume of 80 μl in the presence of the indicated concentration of PAPS or various test compounds,
50 mM HEPES (pH 7.4), 0.015% (v/v) Brij-35 and 5 mM MgCl2 (unless speciﬁed otherwise). The degree of
oligosaccharide sulfation was directly calculated using the EZ Reader software by measuring the sulfo oligosac-
charide : oligosaccharide ratio at each time-point. The activity of HS2ST enzymes in the presence of biochem-
icals and small-molecule inhibitors was quantiﬁed in ‘kinetic mode’ by monitoring the amount of sulfated
glycan generated over the assay time, relative to control assay with no additional inhibitor molecule (DMSO
control). Data were normalised with respect to these control assays, with sulfate incorporation into the substrate
limited to ∼20% to prevent depletion of PAPS and substrate and to ensure assay linearity. Km and IC50 values
were determined by nonlinear regression analysis with GraphPad Prism software.
NMR-based oligosaccharide sulfation analysis
For NMR experiments, ﬂuorescein-labelled hexasaccharide L-IdoA substrate and the HS2ST-catalysed sulfation
product (10 mM) dissolved in 50 mM HEPES, pH 7.4, 5 mM MgCl2 and 0.002% (v/v) Brij-35 were lyophilised
overnight and re-dissolved in an equivalent amount of D2O. NMR experiments were performed at 25°C on a
Bruker Avance III 800 MHz spectrometers equipped with a TCI CryoProbe. 1D and 2D proton and TOCSY
spectra (mixing time 80 ms) were measured using standard pulse sequences provided by the manufacturer.
Spectra were processed and analysed using TopSpin 3.4 software (Bruker).
HPLC-based oligosaccharide sulfation analysis
The ﬂuorescein-labelled hexasaccharide L-IdoA substrate and the HS2ST-catalysed sulfation product (10 mM)
were analysed after anion-exchange chromatography by HPLC as previously described [51]. Oligosaccharides
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were digested in the presence of a mixture of heparitinase I, II and III. Samples were loaded on a Proteomix
SAX-NP5 (SEPAX) column and eluted with an NaCl gradient. Column efﬂuent was mixed (1 : 1) with 2%
(v/v) 2-cyanoacetamide in 250 mM of NaOH and subsequently monitored with a ﬂuorescence detector
( JASCO; FP-1520) either at 346 nm excitation and 410 nm emission (detection of mono and disaccharides
linked to cyanoacetamide) or at 490 nm excitation and 525 nm emission (for detection of trisaccharides linked
to ﬂuorescein).
Small-molecule screening assays
The PKIS chemical library (Supplementary Figure S6, designated as SB, GSK or GW compound sets) comprises
367 largely ATP-competitive kinase inhibitors, covering 31 chemotypes originally designed to inhibit 24 distinct
protein kinase targets [52]. Compounds were stored frozen as a 10 mM stock in DMSO. The library is charac-
terised as highly drug-like (∼70% with molecular mass <500 Da and clogP values <5). For initial screening,
compounds dissolved in DMSO were pre-incubated with HS2ST for 10 min and then employed for DSF or
sulfotransferase-based enzyme reactions, which were initiated by the addition of the universal sulfate donor
PAPS. For inhibition assays, competition assays or individual IC50 value determination, a compound range was
prepared by serial dilution in DMSO and added directly into the assay to the appropriate ﬁnal concentration.
All control experiments contained 4% (v/v) DMSO, which had essentially no effect on HS2ST activity.
Individual chemicals and glycan derivatives were prepared and evaluated using NMR, HPLC, DSF or
microﬂuidics-based assay protocols, as described above.
Figure 1. Analysis of puriﬁed recombinant MBP-HS2ST protein.
(A) Structures of PAPS and PAPS-related biochemicals. (B) Coomassie blue staining of recombinant MBP-HS2ST1 protein.
Approximately 2 μg of puriﬁed enzyme was analysed after SDS–PAGE. (C) Thermal denaturation proﬁles of MBP-HS2ST (5 μM)
and thermal shift in the presence of 0.5 mM PAPS (red), 10 μM heparin (blue) or 5 mM maltose (green). Buffer control is shown
in black dashed lines. (D) Thermal denaturation proﬁle of puriﬁed recombinant MBP. Experimental conditions as for (C). (E) Tm
values measured for 5 μM MBP-HS2ST fusion protein (red, blue) or MBP (red, blue, green) in the presence of 0.5 mM PAPS,
10 μM heparin or 5 mM maltose. ΔTm values were obtained by DSF and calculated by subtracting control Tm values (buffer, no
ligand) from the measured Tm. (F) ΔTm values relative to buffer addition for recombinant PKAc (5 μM) measured in the presence
of 0.5 mM PAPS, 0.5 mM ATP or 0.5 mM ATP and 10 mM MgCl2. Similar results were seen in three independent experiments.
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Docking studies
Docking models for rottlerin, suramin and GW407323A were built using Spartan16 (https://www.wavefun.com)
and energy minimised using the Merck molecular forceﬁeld. GOLD 5.2 (CCDC Software) was used to dock
molecules [53], with the binding site deﬁned as 10 Å around the 50 phosphorous atom of PAP, using
co-ordinates from chicken MBP-HS2ST PDB ID: 4NDZ [20]. A generic algorithm with ChemPLP as the
ﬁtness function [54] was used to generate 10 binding modes per ligand in HS2ST. Protons were added to the
protein. Default settings were retained for the ‘ligand ﬂexibility’ and ‘ﬁtness and search options’; however, ‘GA
settings’ were changed to 200%.
Results
Analysis of human HS2ST ligand binding using a TSA
To our knowledge, DSF has not previously been used to examine the thermal stability and thermal shift proﬁles
of sulfotransferases in the presence or absence of biochemical ligands, such as those related to the sulfate donor
PAPS (Figure 1A). We puriﬁed a recombinant HS2ST catalytic domain (amino acids 69–356) fused to an
N-terminal maltose-binding protein (MBP) tag to near homogeneity (Figure 1B) and evaluated its thermal
denaturation proﬁle with the MBP tag still attached in the presence of PAPS, heparin or maltose (Figure 1C).
As a control, we examined the proﬁle of MBP incubated with the same chemicals (Figure 1D). Unfolding of
MBP-HS2ST in buffer generated a biphasic proﬁle, and the upper region of this proﬁle could be positively
shifted (stabilised) by incubation with the HS2ST cofactor PAPS or the known HS2ST-interacting oligosacchar-
ide ligand heparin (Figure 1C). In contrast, maltose incubation with MBP-HS2ST induced the same character-
istic stabilisation proﬁle observed when MBP was incubated with maltose and then analysed by DSF
(Figure 1D). As expected, neither PAPS nor heparin induced stabilisation of MBP, conﬁrming that effects on
MBP-HS2ST were due to interaction with the sulfotransferase domain, rather than the afﬁnity tag of the recom-
binant protein (Figure 1D, relevant ΔTm values presented in Figure 1E). Consistently, PAPS did not stabilise
the catalytic domain of the ATP-dependent catalytic subunit of cAMP-dependent protein kinase (PKAc),
which instead binds with high afﬁnity to the cofactor Mg-ATP [48], inducing a ΔTm of >4°C (Figure 1F).
We next analysed the sensitivity of this assay for measuring HS2ST stability shifts over a wide range of PAPS
concentrations, which conﬁrmed dose-dependent stabilisation of recombinant HS2ST by PAPS, with detection
of binding in the low micromolar range of the cofactor, equivalent to a molar ratio of ∼1 : 1 HS2ST : PAPS
(Supplementary Figure S1A). Subsequently, we explored the potential of this assay to detect binding of a puta-
tive IdoA-containing oligosaccharide substrate for HS2ST, conﬁrming dose-dependent effects of this polymeric
glycan over a range of concentrations, consistent with binding and conformational stability. Similar to PAPS,
detection of binding was observed in the low micromolar range, equivalent to a molar ratio of ∼1 : 1 HS2ST :
glycan (Supplementary Figure S1B). We also evaluated binding of a panel of adenine-based cofactors (PAP and
ATP), which suggested the binding of divalent cation Mg2+ ions in an EDTA-sensitive manner (Supplementary
Figure S1C), inducing a ΔΤm of ∼3°C, similar to that observed with the HS2ST cofactor PAPS. In contrast,
removal of the sulfo moiety of PAPS, which creates the enzymatic end-product PAP, did not abrogate HS2ST
binding (Supplementary Figure S2A), consistent with structural analysis of the enzyme [28]. Neither PAP nor
PAPS binding required Mg2+ ions, although the effect on stabilisation with Mg2+ ions was additive
(Supplementary Figures 1C and 2A). The non-functional enzyme cofactor APS, in which the 30-phosphate
group of adenine is absent, did not induce HS2ST stabilisation, conﬁrming a requirement for this charged
modiﬁcation (Supplementary Figure S2A). We also established that CoA and acetyl CoA, which both contain a
30-phosphoadenine moiety, clearly induced thermal stabilisation of HS2ST; loss of the 30-phosphate group in
dephospho-CoA abolished this effect (Supplementary Figure S2A). Finally, we demonstrated that ATP, GTP
and ADP, but not AMP or cAMP, were all effective at protecting HS2ST from thermal denaturation, suggesting
that they are also HS2ST ligands (Supplementary Figure S2A).
Analysis of human HS2ST glycan binding using TSA
To extend our HS2ST thermal analysis to identify potential glycan substrates, we evaluated enzyme stability in
the presence of synthetic glycan chains of different lengths and sulfation patterns (Table 1). Of particular inter-
est for further assay development, thermal shift (stabilisation) was detected in this assay when hexasaccharide
(dp6) or a higher degree of polymerisation oligosaccharide was incubated with the enzyme (Supplementary
Figure S2B), suggesting that a dp6 glycan might represent the shortest potential partner suitable for HS2ST
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Figure 2. Development of a novel microﬂuidic mobility shift assay to quantify HS2ST enzymatic activity. Part 1 of 2
(A) Schematic showing PAPS-dependent sulfate incorporation into the ﬂuorescein-labelled hexasaccharide IdoA substrate by
HS2ST, with the concomitant generation of PAP. R = ﬂuorescein. (B) NMR analysis of the non-sulfated and sulfated
hexasaccharides. The addition of a 2-O-sulfate group to the iduronate (L-IdoA) residue of the ﬂuorescent hexasaccharide
results in a signiﬁcant chemical shift change, most notably to the anomeric proton (H-1) and that of H-2 attached to the
sulfated carbon atom of L-IdoA, in agreement with expected values from the literature [47]. 1H NMR spectrum of non-sulfated
substrate (bottom spectrum, black) and sulfated product (upper spectrum, red). Distinct L-IdoA protons (H-3 and H-4 of the
spin system) were identiﬁed by TOCSY and are shown vertically above their respective H-1 signals (for the non-sulfated
substrate, right blue boxed, and for the sulfated product, left blue boxed). The full carbohydrate proton spectra are shown in
Supplementary Figure S3. (C and D) Screen shots of EZ reader II raw data ﬁles, demonstrating that HS2ST induces a rapid
mobility change in the IdoA-containing ﬂuorescent hexasaccharide. Separation of the higher mobility, sulfated (product, P) from
the lower mobility (substrate, S) hexasaccharide occurs as a result of enzymatic substrate sulfation (left panels 180 s assay
time, right panels 240 s assay time), as demonstrated by omission of HS2ST from the assay (−HS2ST). Assays were initially
performed at 20°C using 90 nM of puriﬁed HS2ST, 2 μM ﬂuorescein-labelled hexasaccharide substrate and 500 μM PAPS.
(E) Stoichiometric sulfate-labelling of IdoA-containing ﬂuorescein-labelled hexasaccharide. Reactions were performed with
0.6 μM HS2ST, 375 μM IdoA-hexasaccharide substrate and 1 mM PAPS and incubated at room temperature for 48 h. The
reaction was spiked with an additional 0.5 mM (ﬁnal concentration) of PAPS after 24 h of incubation. M = non-sulfated marker
substrate. A ﬁnal hexasaccharide concentration of 2 μM was analysed by the ﬂuorescent sulfation mobility assay. (F) Analysis
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2423
Biochemical Journal (2018) 475 2417–2433
https://doi.org/10.1042/BCJ20180265
binding, a prerequisite for enzymatic modiﬁcation. Interestingly, many of the chemically modiﬁed heparins
tested served as efﬁcient HS2ST-binding partners relative to the heparin control. The fully chemically sul-
fated I2s,3sA
6s
3sNs hexamer induced a similar HS2ST stability shift to heparin, whereas the singly and doubly
desulfated hexamers induced slightly smaller stability shifts (Supplementary Figure S2C). Moreover, a
putative I2OHA
6OHNs substrate, which contains a 2-O moiety that is predicted to be the substrate for
2-O-sulfotransferases, also led to marked thermal stabilisation of HS2ST, suggestive of productive binding
to HS2ST that might permit it to be sulfated in the presence of PAPS (Supplementary Figure S2C).
A novel microﬂuidic kinetic assay to directly measure oligosaccharide
sulfation by HS2ST
To quantify the effects of various ligands on HS2ST enzyme activity, we sought to develop a new type of rapid
non-radioactive solution assay that could discriminate the enzymatic incorporation of sulfate into a synthetic
oligosaccharide substrate. Current protocols are time-consuming and cumbersome, requiring mass spectrom-
etry, NMR or 35S-based radiolabelling/HPLC separation procedures. Importantly, we next tested whether a
version of an I2OHA
6OHNS containing a hexasaccharide substrate coupled to a linker and ﬂuorescein at the
reducing end, which interacts with HS2ST (Supplementary Figure S2C), could also be enzymatically sulfated by
HS2ST using ‘gold-standard’ NMR-based sulfation detection [47]. The ﬂuorescent I2OHA
6OHNs could not be
evaluated for binding to HS2ST by DSF, due to interference of the ﬂuorescent group in the unfolding assay,
which measures SYPRO-Orange ﬂuorescence at a similar wavelength. Instead, to conﬁrm sulfation of the
ﬂuorescein-labelled substrate, it was pre-incubated with PAPS and HS2ST to catalyse site-speciﬁc sulfation
(Figure 2A). The NMR spectrum of the sulfated product compared with that of the non-modiﬁed substrate
provided unequivocal evidence for sulfation at the 2-O position of the sugar, most notably due to the diagnostic
shifts of anomeric H-1 and H-2 protons in the presence of the 2-O-sulfate group linkage to the carbon atom
(Figure 2B and Supplementary Figure S3). The 2-O-sulfated IdoA hexameric product was also conﬁrmed using
an established HPLC-based approach [51], which demonstrated stoichiometric sulfation of an enzyme-derived
substrate derivative (Supplementary Figure S4).
Next, we evaluated the incorporation of the sulfate moiety from PAPS into a ﬂuorescently labelled glycan
substrate using a microﬂuidic assay that detects real-time changes in substrate covalent modiﬁcation (notably
the introduction of a negative charge) when an electric ﬁeld is applied to the solution reaction. This ratiometric
assay, which we and others have previously employed to detect the formal double-negative charge induced by
real-time peptide phosphorylation [43,55–57], was able to detect real-time incorporation of sulfate into the
oligosaccharide substrate, based on the different retention time of the product compared with the substrate
(Figure 2C). No sulfated product was detected in the absence of HS2ST (Figure 2D), and prolonged incubation
of substrate with HS2ST led to stoichiometric conversion of the substrate into the fully sulfated product (P),
which migrated very differently to the substrate (S) ‘marker’ (Figure 2E). Analysis of product/(product + sub-
strate) ratios of the peak heights allowed us to monitor sulfation over any appropriate assay time (Figures 2F),
and the degree of sulfation could easily be varied as a function of PAPS concentration in the assay.
Furthermore, no sulfated product was detected in the presence of buffer or PAPS alone (Figure 2F), allowing us
to determine a Km value of ∼1 μM for PAPS-mediated substrate hexasaccharide sulfation (Figure 2G). We also
noted that high (>1 mM) concentrations of Mg2+ ions led to concentration-dependent increases in enzyme
HS2ST activity (Figure 2H), consistent with the effects of Mg2+ ions identiﬁed in DSF assays (Supplementary
Figure S2A). Next, we conﬁrmed that sulfation was optimal when an appropriate modiﬁable IdoA substrate was
present, with sulfation reduced by >90% when a GlcA residue was incorporated into the central disaccharide of
Figure 2. Development of a novel microﬂuidic mobility shift assay to quantify HS2ST enzymatic activity. Part 2 of 2
of time-dependent sulfate incorporation into 2 μM IdoA-containing ﬂuorescein-conjugated hexasaccharide. Percentage
sulfation was calculated from the ratio of substrate hexasaccharide to product (2-O-sulfo)-hexasaccharide at the indicated time
points in the presence or absence of 20 nM HS2ST and 10 μM PAPS. (G) Calculation of Km [PAPS] value for HS2ST. PAPS
concentration was varied in the presence of a ﬁxed concentration of HS2ST (20 nM), and the degree of substrate sulfation
calculated from a differential kinetic analysis, n = 2 assayed in duplicate. (H) Duplicate HS2ST assays conducted in the
presence of increasing concentrations of activating Mg2+ ions. Activity is presented in duplicate relative to buffer controls.
Similar results were seen in several independent experiments.
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the substrate instead (compare Supplementary Figure 5A,B). To further validate our assay, we evaluated a cata-
lytically inactive point mutant of HS2ST, in which the putative catalytic base (His142) was mutated to Ala [28].
Puriﬁed H142A MBP-HS2ST appeared to be appropriately folded, and although it bound to PAPS and heparin
(Supplementary Figure S6A–C), it was unable to efﬁciently catalyse sulfation of the ﬂuorescent I2OHA
6OHNS
hexasaccharide substrate, possessing <1% of the activity observed with wild-type MBP-HS2ST (Supplementary
Figure S6D).
Screening for small-molecule inhibitors of HS2ST using DSF and microﬂuidic
technology
The discovery of HS2ST inhibitors is hindered by a lack of a rapid and quantiﬁable assay for the facile detec-
tion of sulfate modiﬁcation using a close mimic of a physiological substrate. Our discovery that a synthetic
HS2ST glycan substrate could be readily sulfated and detected by enzymatic assay in solution, without the need
for HPLC, NMR or radioactive procedures, meant that this approach might now be optimised for the discovery
of small-molecule HS2ST inhibitors. We ﬁrst evaluated the ability of an unlabelled (non-ﬂuorescent) heparin
glycan substrate that lacked sulfate at the 2-O position, or a non-substrate heparin that was fully sulfated at all
potential sites, to act as HS2ST inhibitors in our ﬂuorescent glycan sulfation assay. As detailed in Figure 3A,
the fully sulfated glycan was a potent inhibitor, interfering with HS2ST-dependent sulfation of the substrate
with an IC50 value of <10 nM, consistent with tight binding to the enzyme, as previously established using DSF
(Supplementary Figure S2C). In contrast, a less highly sulfated substrate was still able to compete with the
Figure 3. Microﬂuidic sulfotransferase assay to measure inhibition of HS2ST activity in vitro.
Assays were performed using 20 nM HS2ST and the extent of substrate sulfation was determined after 15 min incubation at
room temperature, as described in Figure 2. Dose–response curves for inhibition of HS2ST activity by (A) modiﬁed heparin
derivatives containing different sulfation patterns (assayed in the presence of 0.5 mM MgCl2) or (B) nucleotides (assayed in the
absence of MgCl2). Assays contained HS2ST and 10 μM PAPS and the indicated concentration of inhibitory ligand or buffer.
(C) Inhibition of HS2ST activity by ﬁxed 10 μM PAP, 0.5 mM CoA or 0.5 mM dephospho-CoA in the presence of increasing
concentration of PAPS. Inhibition is calculated as a function of no inhibitor for each concentration of PAPS in the absence of
MgCl2. (D) Evaluation of small-molecule HS2ST inhibitory proﬁles in the presence of 10 μM PAPS. (E) Inhibition of HS2ST
activity by 20 μM rottlerin in the presence of varied concentrations of PAPS, suggesting a competitive mode of inhibition.
Similar results were seen in multiple experiments.
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ﬂuorescent substrate in a dose-dependent manner (ﬁxed at 2 μM in this assay), as indicated by the IC50
value of <100 nM. We next compared the effects of PAP, ATP, CoA and dephospho-CoA, which all exhibit
thermal stabilisation of HS2ST in DSF assays (Supplementary Figure S2A). Interestingly, PAP (IC50 ∼2 μM),
CoA (IC50 = 65 μM) and ATP (IC50 = 466 μM) were HS2ST inhibitors, whereas dephospho-CoA (which lacks
the 30-phosphate moiety in CoA) was not (Figure 3B). Increasing the concentration of PAPS in the assay led to a
decrease in the level of inhibition by both PAP and CoA (Figure 3C), suggesting a PAPS-competitive mode of
inhibition, as predicted from the various shared chemical features of these molecules (Figure 1A).
Recent studies have demonstrated that PAPS-dependent tyrosyltransferases (tyrosyl protein sulfotranferase,
TPSTs) are inhibited by non-nucleotide-based polyanionic chemicals [58]. However, to our knowledge, the
inhibition of carbohydrate sulfotransferases by such compounds has not been reported. Using our microﬂuidic
assay, we conﬁrmed that the polysulfated compound suramin (an inhibitor of angiogenesis) and the polyaro-
matic polyanion aurintricarboxylate (an inhibitor of protein : nucleic acid interactions, DNA polymerase and
topoisomerase II) demonstrated nanomolar inhibition of HS2ST, with IC50 values of 40 ± 1 and 123 ± 7 nM,
respectively (Figure 3D). In addition, the non-speciﬁc protein kinase inhibitor rottlerin also inhibited HS2ST
with an IC50 of 6.4 μM. Increasing the concentration of PAPS in the sulfation assay decreased the inhibitory
effect, consistent with a competitive mode of HS2ST inhibition for rottlerin (Figure 3E).
Protein kinase inhibitors are a new class of potential broad-spectrum HS2ST
inhibitor
The ﬁnding that the non-speciﬁc kinase inhibitor rottlerin [59] was a micromolar inhibitor of HS2ST was of
particular interest, especially given the remarkable progress in the development of kinase inhibitors as chemical
probes, tool compounds and, latterly, clinically approved drugs. Similarities between ATP and PAPS
(Figure 1A), and the ﬁnding that ATP can both bind to, and inhibit, HS2ST activity (Supplementary
Figure S2A and Figure 3B) raised the possibility that other ATP-competitive protein kinase inhibitors might
also interact with HS2ST. To exploit our screening capabilities further, we established a 384-well assay to evalu-
ate inhibition of PAPS-dependent glycan sulfation by HS2ST. The Published Kinase Inhibitor Set (PKIS) is a
well-annotated collection of 367 high-quality ATP-competitive kinase inhibitor compounds that are ideal for
compound repurposing or the discovery of new chemical ligands for orphan targets. We screened PKIS using
DSF and enzyme-based readouts (Figure 4A,B, respectively). As shown in Figure 4A, when screened at 40 μM
compound in the presence of 5 μM HS2ST, only a small percentage of compounds induced HS2ST stabilisation
or destabilisation at levels similar to that seen with an ATP control. We focussed on compounds inducing
HS2ST ΔTm values between +0.5°C and −0.5°C, and re-screened each ‘hit’ compound using ratiometric HS2ST
enzyme assays at a ﬁnal compound concentration of 40 μM. We reported the enzyme activity remaining com-
pared with DMSO, with rottlerin (IC50 =∼8 μM), suramin (IC50 =∼20 nM) and aurintricarboxylate (IC50
=∼90 nM) as positive controls (Figure 4B and Supplementary Figures 7 and 8). We also included the com-
pound GW406108X in our enzyme assay since it was structurally related to several ‘hit’ compounds from the
DSF screen. As shown in Figure 4C, the three PKIS compounds with the highest inhibitory activity (red) exhib-
ited IC50 values of between 20 and 30 μM towards HS2ST in the presence of 1 μM PAPS, similar to inhibition
by rottlerin. Of particular interest, these three compounds were among the top ∼10% of compounds in terms
of their ΔTm values (red spheres, Figure 4A). Chemical deconvolution of compounds revealed that all three
were closely related members of a class of oxindole-based RAF protein kinase inhibitor (Figure 4A).
Subsequently, one other related indole RAF inhibitory compound from PKIS, GW305074, was also shown to
be a mid-micromolar HS2ST inhibitor, whereas the related oxindole GW405841X (Supplementary Figure S8)
did not inhibit HS2ST at any concentration tested (Figure 4C). Finally, we used combined DSF and enzyme
assays to evaluate a broader panel of well-characterised kinase inhibitors (Supplementary Figure S9).
Interestingly, neither the pan-kinase inhibitor staurosporine nor several FDA-approved tyrosine kinase inhibi-
tors caused thermal stabilisation of HS2ST at any concentration tested. Moreover, chemically diverse RAF inhi-
bitors, including clinical RAF compounds such as dabrafenib and vemurafenib, were unable to inhibit HS2ST
in our sensitive HS2ST enzyme, even at concentrations as high as 400 μM (Supplementary Figure S9B).
Docking analysis of HS2ST ligands
The X-ray structure (PDB ID: 4NDZ) of trimeric chicken MBP-HS2ST fusion protein bound to non-sulfated
PAP (adenosine-30-50-diphosphate, a potent HS2ST inhibitor that was identiﬁed in the present study) and a
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polymeric oligosaccharide have previously been reported [20,28]. We employed a 3.45 Å structural dataset to
dock rottlerin, suramin and the most potent oxindole-based ‘hit’ from the screen (GW407323A, see Figure 4B)
into the extended enzyme active site. As shown in Figure 5A, HS2ST possesses substrate-binding features that
accommodates an extended oligosaccharide that place it in close proximity to the desulfated PAP end-product,
which substitutes for the endogenous PAPS cofactor during crystallisation. The 30-phosphoadenine moiety of
PAP also helps anchor the nucleotide in an appropriate position. A molecular docking protocol for PAP in
HS2ST was developed that matched the crystallographic binding pose of PAP extremely well (RMSD 0.31 Å,
Figure 5B). By comparing a crystallised ligand (PAP) with docked rottlerin, suramin and GW407323A, we con-
ﬁrmed that compounds could be docked into the active site of HS2ST broadly corresponding to either the
PAPS-binding region (rottlerin and GW407323A, Figure 5C,D) or bridging both the substrate and cofactor-
binding sites (suramin, Figure 5E). In these binding modes, compounds make many stabilising amino acid
interactions that permit them to compete with PAPS or oligosaccharide substrate for binding to HS2ST
(Figure 5C, residue numbering based on the HS2ST trimer). For example, rottlerin is predicted to form a
hydrogen bond with the amide backbone of Thr 1290, GW407323A has multiple potential hydrogen bonding
interactions with residues including Arg 1080, Asn 1112 and Ser 1172, while suramin is predicted to form
hydrogen bonds with residues Asn 1091, Tyr 1094 and Arg 1288, allowing this highly elongated inhibitor to
straddle separate regions of the active site.
Figure 4. Mining the PKIS inhibitor library for HS2ST inhibitor compounds.
(A) Evaluation of small-molecule ligands in a high-throughput HS2ST DSF assay. HS2ST (5 μM) was screened in the presence
or absence of 40 μM compound. The ﬁnal concentration of DMSO in the assay was 4% (v/v). ΔTm values (positive and
negative) were calculated by subtracting the control Tm value (DMSO alone) from the measured Tm value. Data shown on a
scatter plot of the mean ΔTm values from two independent DSF assays. (B) Enzymatic analysis of HS2ST inhibition by selected
PKIS compounds. HS2ST (20 nM) was incubated with the indicated PKIS compound (40 μM) in the presence of 10 μM PAPS
for 15 min at room temperature. HS2ST sulfotransferase activity was assayed using the ﬂuorescent hexasaccharide substrate
and normalised to DMSO control (4%, v/v). (C) Full dose–response curves for selected compounds. HS2ST (20 nM) was
incubated with increasing concentration of inhibitor in the presence of 1 μM PAPS for 15 min at 20°C. HS2ST activity
calculated as above. Data from two independent experiments are combined. Similar results were seen in an independent
experiment.
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Discussion
In the present paper, we report a simple method for the detection of enzyme-catalysed glycan sulfation using a
model IdoA-containing hexasaccharide fused to a reducing-end ﬂuorophore. The chemical similarity between
ATP, a universal phosphate donor, and PAPS, a universal sulfate donor, led us to investigate whether enzymatic
glycan sulfation could be detected using a high-throughput kinetic procedure previously validated for peptide
phosphorylation by ATP-dependent protein kinases. We focussed our attention on HS2ST, which transfers
sulfate from PAPS to the 2-O position of IdoA during heparan sulfate biosynthesis in the secretory pathway.
To facilitate rapid puriﬁcation of recombinant HS2ST, the enzyme was expressed as an N-terminal MBP
fusion protein, and we conﬁrmed that it was folded, and could bind to a variety of known exogenous ligands
including PAPS and PAP, the end-product of the sulfotransferase reaction. Protein kinases are also known to
bind to their end-product (ADP), and kinase structural analysis has long taken advantage of the stability of
kinase and ATP analogues, or ADP-like complexes, for protein co-crystallisation. Similar co-crystallisation
approaches revealed the structure of HS2ST, and related sulfotransferases, in complex with PAP and model sac-
charide substrates [20,21], and our study extends these approaches, by revealing a competitive mode of HS2ST
interaction with a variety of 30-phosphoadenosine-containing nucleotides, including CoA. They also suggest
that generalised docking of a 30phosphoadenosine moiety is a feature of HS2ST that could be mimicked using
other small-molecule inhibitors. DSF-based thermal shift assays are ideal for the analysis of a variety of proteins
and ligands, including growth factors [4,60], protein kinase domains [45,48,57], pseudokinase domains [61,62],
Figure 5. Molecular docking analysis of HS2ST with small-molecule inhibitor compounds.
(A) Structural representation of the catalytic domain of chicken MBP-HS2ST crystallised with bound heptasaccharide and
non-sulfated PAP cofactor (protein rendered as a cartoon). Red— α-helix, yellow— β-sheet, green— loop. PAP
(adenosine-30-50-diphosphate) and heptasaccharride are rendered as coloured sticks. Grey — carbon, red— oxygen, blue—
nitrogen, yellow— sulfur. Black dotted line indicates close proximity of glycan 2-OH group and PAP. (B) Structure of HS2ST
with near-identical crystallographic (carbons in cyan) and docking (carbons in purple) poses of PAP (protein rendered as a
cartoon). Red— α-helix, yellow – β-sheet, green— loop. PAP rendered as coloured sticks. Cyan/grey/purple— carbon, red —
oxygen, blue— nitrogen, dark yellow— sulfur). Black dotted lines indicate hydrogen bonds. Molecular docking of (C) rottlerin
and (D) the indole RAF inhibitor GW407323A or (E) suramin into the HS2ST catalytic domain (protein depicted as a cartoon).
Red— α-helix, yellow— β-sheet, green— loop. Docked molecules coloured as sticks. Pink/yellow/salmon/grey— carbon, red
— oxygen, blue— nitrogen, dark yellow— sulfur, white— hydrogen). Black dotted lines indicate hydrogen bonds. Amino acid
numbering corresponds to that of trimeric HS2ST.
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BH3 [63] and bromodomain-containing proteins [64]. However, to our knowledge, this is the ﬁrst report to
demonstrate the utility of a DSF-based strategy for the analysis of any sulfotransferase.
Competitive HS2ST inhibition by biochemical ligands
By developing a new type of rapid, kinetic glycan sulfation assay, we conﬁrmed that many HS2ST ligands also
act as competitive inhibitors of PAPS-dependent oligosaccharide sulfation, setting the stage for a broader
screening approach for the discovery of HS2ST inhibitors. Standard assays for carbohydrate sulfation utilise
HPLC-based detection of 35S-based substrate sulfation derived from 35S-labelled PAPS, requiring enzymatic
cofactor synthesis and time-consuming radioactive solid-phase chromatography procedures [20,35,41]. While
enzymatic deconvolution, MS and NMR-based procedures remain useful for mapping sulfation patterns in
complex (sometimes unknown) glycan polymers, these procedures are very time-consuming and relatively
expensive. In contrast, our ﬁnding that sulfation can be detected using a simple glycan mobility shift assay, and
then quantiﬁed in real time by comparing the ratio of a sulfated and non-sulfated substrate, is rapid, reprodu-
cible and relatively inexpensive. Our kinetic assay makes use of a commercial platform originally developed for
the analysis of peptide phosphorylation or peptide proteolysis, which allows for the inclusion of high concen-
trations of non-radioactive cofactors, substrates and ligands in assays [45]. Consequently, we were able to use
this technology to derive a Km value for PAPS in our standard HS2ST assay of 1.0 μM (Figure 2G), slightly
lower than the reported literature value of 18.5 μM for HS2ST using desulfated heparin as a substrate [20], but
similar to the reported literature value of ∼4.3 μM for the PAPS-dependent GlcNAc-6-sulfotransferase NodH
from Rhizobium melitoli [35] and 1.5 and 10 μM for human hormone iodotyrosine sulfotransferases and
tissue-puriﬁed tyrosyl sulfotransferase [65,66]. In the course of our studies, we developed several new reagents,
including a hexameric ﬂuorescent substrate in which the central IdoA residue was replaced by a GlcA residue
(Supplementary Figure S5). Interestingly, a decreased rate of substrate modiﬁcation was observed using this
oligosaccharide substrate, consistent with the ability of HS2ST to sulfate either IdoA or GlcA [19], but with a
marked preference for the former. Previous HPLC-based studies identiﬁed an N-sulfo group in the oligosac-
charide substrate as a prerequisite for catalysis, with subsequent preferential transfer of sulfate to the 2-O pos-
ition of IdoA [20,22,28,67]; these published observations are entirely consistent with our ﬁndings using a
hexameric ﬂuorescent substrate.
In the future, it might be possible to quantify other site-speciﬁc covalent modiﬁcations in complex glycans
using ﬂuorescent oligosaccharides that contain distinct sugar residues, and by employing mobility-dependent
detection in the presence of a variety of enzymes. These could include 3-O- and 6-O-sulfotransferases [21] or
structurally distinct glycan phosphotransferases, such as the protein-O-mannose kinase POMK/Sgk196 [68],
which catalyses an essential phosphorylation step during biosynthesis of an α-dystroglycan substrate [69].
Using this general approach, the screening and comparative analysis of small-molecule inhibitors of these dis-
tinct enzyme classes would be simpliﬁed considerably relative to current procedures.
HS2ST inhibition by known kinase inhibitors, including a family of known RAF
inhibitors
Our ﬁnding that HS2ST was inhibited at sub-micromolar concentrations by the compounds suramin [70] and
the DNA polymerase inhibitor aurintricarboxylic acid [71] was intriguing, and consistent with recent reports
demonstrating inhibitory activity of these compounds towards TPSTs, which employ PAPS as a cofactor, but
instead sulfate tyrosine residues in speciﬁc motifs embedded in a variety of proteins [58]. During the course of
our studies screening a panel of kinase inhibitors, we found that the non-speciﬁc kinase compound rottlerin is a
micromolar inhibitor of HS2ST in vitro, with inhibition dependent on the concentration of PAPS in the assay,
suggesting a competitive mode of interaction. Rottlerin (also known as mallotoxin) is a polyphenolic compound
from Mallotus philippensis and, although originally identiﬁed as an inhibitor of PKC isozymes [72], possesses a
wide variety of biological effects likely due to its non-speciﬁc inhibition of multiple protein kinases [59]. This lack
of speciﬁcity prevents exploitation of rottlerin in cells as a speciﬁc probe, although our ﬁnding that HS2ST is a
target of this compound opens up the possibility that this, or other, protein kinase inhibitors might also possess
inhibitory activity towards HS2ST, either due to an ability to target the PAPS or oligosaccharide-binding sites in
the enzyme. To evaluate these possibilities further, we screened PKIS, a collection of drug-like molecules with
broad inhibitory activity towards multiple protein kinases. Interestingly, only three compounds (<1% of the
library) consistently showed marked inhibitory activity at 40 μM in our HS2ST enzyme assay (Figure 4A–C, red).
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Remarkably, all three compounds belonged to the same benzylidene-1H-inol-2-one (oxindole) chemical class,
which were originally reported as potent ATP-dependent RAF kinase inhibitors that block the MAPK signalling
pathway in cultured cells [73]. Retrospectively, of all the related chemotypes present in the PKIS library, we con-
ﬁrmed that GW305074X (but not GW405841X) was also a micromolar HS2ST inhibitor, consistent with the
broad sensitivity of HS2ST to this optimised class of RAF inhibitor.
Although limited structure–activity relationships can be derived from our initial studies, these ﬁndings dem-
onstrate that HS2ST inhibitors can be discovered, and that several of these inhibitors could be of broad interest
to the sulfotransferase (and protein kinase) ﬁelds. An additional outcome of our work is that pharmaceutical
companies might conduct more extensive high-throughput screens using much larger libraries of kinase inhibi-
tors to identify distinct, and more potent, leads. Our study also validates previous observations from the turn of
the century, in which carbohydrate inhibitors of NoDH sulfotransferase were reported from a low diversity
kinase-directed library [35]. Surprisingly, this early breakthrough did not lead to the development of any
glycan sulfotransferase tool compounds for cell-based analysis. However, our discovery that oxindole-based
RAF inhibitors are also HS2ST inhibitors could provide new impetus for the design and synthesis of much
more speciﬁc and potent HS2ST inhibitors from this class of RAF kinase inhibitor, especially if issues of speci-
ﬁcity can be evaluated using mutagenic target-validation approaches previously validated for various protein
kinases [74–76].
A requirement for rapid progress during this process will be structure-based analysis of HS2ST in the pres-
ence of compounds, in order to determine mechanism and mode(s) of interaction. Our initial docking studies
suggest similar binding modes for both rottlerin and the oxindole-based ligand GW407323A (Figure 5), with
the potential for cross-over between PAPS and substrate-binding sites present on the surface of HS2ST. It will
be intriguing to explore these binding modes by structural analysis and guided mutational approaches [77], in
order to evaluate potential drug-binding site residues in HS2ST and to tease apart requirements for enzyme
inhibition. It will also be important to assess whether compounds identiﬁed as in vitro HS2ST inhibitors,
including previously reported RAF inhibitors, can also interfere with HS sulfation and downstream signalling
in cells. Interestingly, suramin is a potent anti-angiogenic compound and is reported to have cellular effects on
FGF signalling [78], whereas aurintricarboxylate has multiple cellular effects currently attributed to nucleotide-
dependent processes. Attempting to link some of these cellular phenotypes to the inhibition of 2-O glycan sul-
fation is a worthy future experimental strategy, although success with PAPS-competitive compounds is likely to
depend on the concentration of PAPS in the Golgi network and the relative rate of, minimally, 2-O-sulfate
turnover (sulfation versus desulfation) among physiological HS2ST substrates.
Conclusion
Our work raises the possibility that HS2ST inhibitors could be developed strategically following the successful
blueprint laid down for protein kinase inhibitors in the previous decades. Dozens of sulfotransferases are found
in vertebrate genomes, and the development of chemical biology approaches to rapidly inactivate Golgi
membrane-bound sulfotransferases and induce targeted inhibition of sulfation has been stymied by a lack of
tool compounds, whose exploitation has the opportunity to revolutionise cell biology when properly validated
[79,80]. We propose that if such compounds can be developed, perhaps through high-throughput screening
and discovery of new inhibitors, or even via chemical manipulation of the leads reported in the present study,
then a new era in sulfation-based cell biology might be on the horizon. By generating tools to chemically
control glycan sulfation modulated by HS2ST directly, inhibitor-based interrogation of sulfation-dependent
enzymes could also have signiﬁcant impact in many active areas of translational research.
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